Skip to main content
Top
Published in: Urolithiasis 3-4/2008

01-08-2008 | Original Paper

Citraturic, alkalinizing and antioxidative effects of limeade-based regimen in nephrolithiasis patients

Authors: Piyaratana Tosukhowong, Chatchai Yachantha, Thosaphol Sasivongsbhakdi, Supoj Ratchanon, Suchada Chaisawasdi, Chanchai Boonla, Kriang Tungsanga

Published in: Urolithiasis | Issue 3-4/2008

Login to get access

Abstract

Potassium citrate has long been used as a prophylactic remedy for nephrolithiasis recurrence. Lemonade consumption is also suggested as an option. We compared the efficacy of consumption of solution containing manufactured lime powder with that of potassium citrate, on the improvement of metabolic risk factors, oxidative stress and renal tubular damage in nephrolithiasis patients. Patients with kidney stone were enrolled and randomly assigned to three treatment programs for 3 month period consisting of consumption of solution containing lime powder (Group 1, = 13), potassium citrate (Group 2, n = 11) and lactose as placebo regimen (Group 3, n = 7). Lime powder and potassium citrate contained equal amounts of potassium (21 mEq) and citrate (63 mEq). After treatment, there was an increase in urinary pH, potassium and citrate in Group 1 and 2. Increased plasma potassium and red blood cell glutathione (R-GSH) and decreased urinary malondialdehyde were found in Group 1, but not observed in Group 2. R-GSH was decreased in Group 2. Urinary N-acetyl-β-glucosaminidase activity and fractional excretion of magnesium, as renal tubular damage indicators, were decreased only in Group 1. In Group 3, all measured parameters were unaltered except for an increased urinary chloride. In conclusion, consumption of our in-house lime powder exerted citraturic and alkalinizing actions as efficient as consumption of potassium citrate. In addition, it provided an antioxidative effect and was able to attenuate renal tubular damage. These pharmacological properties may be clinically useful to diminish the stone-forming potential in kidney stone patients and hence for preventing recurrent calculi.
Literature
2.
go back to reference Khan SR (2006) Renal tubular damage/dysfunction: key to the formation of kidney stones. Urol Res 34:86–91PubMedCrossRef Khan SR (2006) Renal tubular damage/dysfunction: key to the formation of kidney stones. Urol Res 34:86–91PubMedCrossRef
3.
go back to reference Huang HS, Ma MC, Chen CF, Chen J (2003) Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones. Urology 62:1123–1128PubMedCrossRef Huang HS, Ma MC, Chen CF, Chen J (2003) Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones. Urology 62:1123–1128PubMedCrossRef
4.
go back to reference Tungsanga K, Sriboonlue P, Futrakul P, Yachantha C, Tosukhowong P (2005) Renal tubular cell damage and oxidative stress in renal stone patients and the effect of potassium citrate treatment. Urol Res 33:65–69PubMedCrossRef Tungsanga K, Sriboonlue P, Futrakul P, Yachantha C, Tosukhowong P (2005) Renal tubular cell damage and oxidative stress in renal stone patients and the effect of potassium citrate treatment. Urol Res 33:65–69PubMedCrossRef
5.
go back to reference Boonla C, Wunsuwan R, Tungsanga K, Tosukhowong P (2007) Urinary 8-hydroxydeoxyguanosine is elevated in patients with nephrolithiasis. Urol Res 35:185–191PubMedCrossRef Boonla C, Wunsuwan R, Tungsanga K, Tosukhowong P (2007) Urinary 8-hydroxydeoxyguanosine is elevated in patients with nephrolithiasis. Urol Res 35:185–191PubMedCrossRef
6.
go back to reference Pak CY, Fuller C, Sakhaee K, Preminger GM, Britton F (1985) Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol 134:11–19PubMed Pak CY, Fuller C, Sakhaee K, Preminger GM, Britton F (1985) Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol 134:11–19PubMed
7.
go back to reference Mattle D, Hess B (2005) Preventive treatment of nephrolithiasis with alkali citrate—a critical review. Urol Res 33:73–79PubMedCrossRef Mattle D, Hess B (2005) Preventive treatment of nephrolithiasis with alkali citrate—a critical review. Urol Res 33:73–79PubMedCrossRef
8.
go back to reference Preminger GM, Harvey JA, Pak CY (1985) Comparative efficacy of “specific” potassium citrate therapy versus conservative management in nephrolithiasis of mild to moderate severity. J Urol 134:658–661PubMed Preminger GM, Harvey JA, Pak CY (1985) Comparative efficacy of “specific” potassium citrate therapy versus conservative management in nephrolithiasis of mild to moderate severity. J Urol 134:658–661PubMed
9.
go back to reference Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY (1993) Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 150:1761–1764PubMed Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY (1993) Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 150:1761–1764PubMed
10.
go back to reference Gaharagozloo M, Doroudchi M, Ghaderi A (2002) Effects of Citrus aurantifolia concentrated exact on the spontaneous proliferation of MDA-MB–453 and RPMI–8866 tumor cell lines. Phytomedicine 9:475–477CrossRef Gaharagozloo M, Doroudchi M, Ghaderi A (2002) Effects of Citrus aurantifolia concentrated exact on the spontaneous proliferation of MDA-MB–453 and RPMI–8866 tumor cell lines. Phytomedicine 9:475–477CrossRef
11.
go back to reference Seltzer MA, Low RK, McDonald M, Shami GS, Stoller ML (1996) Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis. J Urol 156:907–909PubMedCrossRef Seltzer MA, Low RK, McDonald M, Shami GS, Stoller ML (1996) Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis. J Urol 156:907–909PubMedCrossRef
12.
go back to reference Kang DE, Sur RL, Haleblian GE, Fitzsimons NJ, Borawski KM, Preminger GM (2007) Long-term lemonade based dietary manipulation in patients with hypocitraturic nephrolithiasis. J Urol 177:1358–1362, discussion 1362; quiz 1591PubMedCrossRef Kang DE, Sur RL, Haleblian GE, Fitzsimons NJ, Borawski KM, Preminger GM (2007) Long-term lemonade based dietary manipulation in patients with hypocitraturic nephrolithiasis. J Urol 177:1358–1362, discussion 1362; quiz 1591PubMedCrossRef
13.
go back to reference Koff SG, Paquette EL, Cullen J, Gancarczyk KK, Tucciarone PR, Schenkman NS (2007) Comparison between lemonade and potassium citrate and impact on urine pH and 24-h urine parameters in patients with kidney stone formation. Urology 69:1013–1016PubMedCrossRef Koff SG, Paquette EL, Cullen J, Gancarczyk KK, Tucciarone PR, Schenkman NS (2007) Comparison between lemonade and potassium citrate and impact on urine pH and 24-h urine parameters in patients with kidney stone formation. Urology 69:1013–1016PubMedCrossRef
14.
go back to reference Leong LP, Shui G (2002) An investigation of antioxidant capacity of fruits in Singapore markets. Food Chem 76:69–75CrossRef Leong LP, Shui G (2002) An investigation of antioxidant capacity of fruits in Singapore markets. Food Chem 76:69–75CrossRef
15.
go back to reference Jayaprakasha GK, Patil BS (2007) In vitro evaluation of the antioxidant activities in fruit extracts from citron and blood orange. Food Chem 101:410–418CrossRef Jayaprakasha GK, Patil BS (2007) In vitro evaluation of the antioxidant activities in fruit extracts from citron and blood orange. Food Chem 101:410–418CrossRef
16.
go back to reference Preminger GM, Sakhaee K, Pak CY (1988) Alkali action on the urinary crystallization of calcium salts: contrasting responses to sodium citrate and potassium citrate. J Urol 139:240–242PubMed Preminger GM, Sakhaee K, Pak CY (1988) Alkali action on the urinary crystallization of calcium salts: contrasting responses to sodium citrate and potassium citrate. J Urol 139:240–242PubMed
17.
go back to reference Koenig K, Padalino P, Alexandrides G, Pak CY (1991) Bioavailability of potassium and magnesium, and citraturic response from potassium–magnesium citrate. J Urol 145:330–334PubMed Koenig K, Padalino P, Alexandrides G, Pak CY (1991) Bioavailability of potassium and magnesium, and citraturic response from potassium–magnesium citrate. J Urol 145:330–334PubMed
18.
go back to reference Pak CY (1994) Citrate and renal calculi: an update. Miner Electrolyte Metab 20:371–377PubMed Pak CY (1994) Citrate and renal calculi: an update. Miner Electrolyte Metab 20:371–377PubMed
19.
go back to reference Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A (1997) Potassium–magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 158:2069–2073PubMedCrossRef Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A (1997) Potassium–magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 158:2069–2073PubMedCrossRef
20.
go back to reference Tosukhowong P, Borvonpadungkitti S, Prasongwatana V, Tungsanga K, Jutuporn S, Dissayabutr T, Reungjui S, Sriboonlue P (2002) Urinary citrate excretion in patients with renal stone: roles of leucocyte ATP citrate lyase activity and potassium salts therapy. Clin Chim Acta 325:71–78PubMedCrossRef Tosukhowong P, Borvonpadungkitti S, Prasongwatana V, Tungsanga K, Jutuporn S, Dissayabutr T, Reungjui S, Sriboonlue P (2002) Urinary citrate excretion in patients with renal stone: roles of leucocyte ATP citrate lyase activity and potassium salts therapy. Clin Chim Acta 325:71–78PubMedCrossRef
21.
go back to reference Zerwekh JE, Odvina CV, Wuermser LA, Pak CY (2007) Reduction of renal stone risk by potassium–magnesium citrate during 5 weeks of bed rest. J Urol 177:2179–2184PubMedCrossRef Zerwekh JE, Odvina CV, Wuermser LA, Pak CY (2007) Reduction of renal stone risk by potassium–magnesium citrate during 5 weeks of bed rest. J Urol 177:2179–2184PubMedCrossRef
22.
go back to reference Hamm LL, Hering-Smith KS (2002) Pathophysiology of hypocitraturic nephrolithiasis. Endocrinol Metab Clin North Am 31:885–893, viii Hamm LL, Hering-Smith KS (2002) Pathophysiology of hypocitraturic nephrolithiasis. Endocrinol Metab Clin North Am 31:885–893, viii
23.
go back to reference Hofbauer J, Hobarth K, Szabo N, Marberger M (1994) Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis—a prospective randomized study. Br J Urol 73:362–365PubMedCrossRef Hofbauer J, Hobarth K, Szabo N, Marberger M (1994) Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis—a prospective randomized study. Br J Urol 73:362–365PubMedCrossRef
24.
go back to reference Wabner CL, Pak CY (1993) Effect of orange juice consumption on urinary stone risk factors. J Urol 149:1405–1408PubMed Wabner CL, Pak CY (1993) Effect of orange juice consumption on urinary stone risk factors. J Urol 149:1405–1408PubMed
25.
go back to reference Lenton KJ, Sane AT, Therriault H, Cantin AM, Payette H, Wagner JR (2003) Vitamin C augments lymphocyte glutathione in subjects with ascorbate deficiency. Am J Clin Nutr 77:189–195PubMed Lenton KJ, Sane AT, Therriault H, Cantin AM, Payette H, Wagner JR (2003) Vitamin C augments lymphocyte glutathione in subjects with ascorbate deficiency. Am J Clin Nutr 77:189–195PubMed
Metadata
Title
Citraturic, alkalinizing and antioxidative effects of limeade-based regimen in nephrolithiasis patients
Authors
Piyaratana Tosukhowong
Chatchai Yachantha
Thosaphol Sasivongsbhakdi
Supoj Ratchanon
Suchada Chaisawasdi
Chanchai Boonla
Kriang Tungsanga
Publication date
01-08-2008
Publisher
Springer-Verlag
Published in
Urolithiasis / Issue 3-4/2008
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-008-0141-9

Other articles of this Issue 3-4/2008

Urolithiasis 3-4/2008 Go to the issue